Abstract: The present invention provides a method of selecting subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues for treatment with a Ret inhibitor. The present invention also provides Ret inhibitors as medicaments for subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues.

Abstract: The present invention relates to a method for treating cancer, for instance breast cancer, in a subject by inhibiting Frizzled-4 and/or Frizzled-1 by administering to said subject a therapeutically effective amount of a modulator of Frizzled-4 and/or Frizzled-1, for example a specific antibody or a siRNA.

Abstract: The invention is based on CGI-27 (named Memo for mediator of ErbB2-dependent cell motility) and its role in cell motility. The invention provides methods of inhibiting cell migration, particularly late phase cell migration e.g. which is induced by signals from the EGF-R. Also provided a related methods and materials for identifying and using inhibitors and other molecules, such as Memo binding partners, which may be used in modulating cell motility.

Abstract: The present invention makes available assays and reagents inhibiting ErbB signals produced by Wnt protein comprising contacting a cell expressing ErbB and Wnt receptor (Frizzled) with a Wnt antagonist in a sufficient amount to reduce the sensitivity of the cell to ErbB signaling.